News

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX ...
On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...
Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...